Literature DB >> 2570008

Frequent non-response to histamine H2-receptor antagonists in cirrhotics.

S Walker1, D R Krishna, U Klotz, J C Bode.   

Abstract

The effect of ranitidine 300 mg po given at 1800 h (famotidine 40 mg/cimetidine 800 mg) on the night time gastric pH was tested using longterm intragastric pH monitoring in 27 patients with and 32 patients without liver cirrhosis. A rise in the gastric pH above 4.0 for more than six hours between 1800 h and 0600 h was considered as sufficient effect (response) of the H2-receptor antagonists on gastric acidity. Among the patients with cirrhosis, there were significantly (p less than 0.005) more non-responders to ranitidine (16 of 27 patients) than in the control group (six of 32). When 13 of the 22 non-responders to ranitidine were subsequently treated with famotidine, only two showed a sufficient rise in their gastric pH. Of the 11 patients not responding to both H2-receptor antagonists, 10 were finally treated with cimetidine and eight did not respond. Plasma levels of all three drugs measured two and four hours after oral administration were not significantly different between cirrhotic and noncirrhotic patients as well as between responders and non-responders. In addition, in all patients plasma levels were far above the corresponding IC50 values. Therefore, differences in the absorption and plasma levels of these drugs cannot account for the frequent non-response in cirrhotics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570008      PMCID: PMC1434164          DOI: 10.1136/gut.30.8.1105

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  The liver's role in histamine absorption from the alimentary tract; its possible importance in cirrhosis.

Authors:  W T IRVINE; H L DUTHIE; H D RITCHIE; N G WATON
Journal:  Lancet       Date:  1959-05-23       Impact factor: 79.321

2.  Gastric secretion in human hepatic cirrhosis.

Authors:  J D OSTROW; R J TIMMERMAN; S J GRAY
Journal:  Gastroenterology       Date:  1960-03       Impact factor: 22.682

3.  [Endogenous plasma histamine and "hepatogenic" peptic ulcer in liver cirrhosis (author's transl)].

Authors:  D Stopik; K E Hampel; D v Kleist
Journal:  Dtsch Med Wochenschr       Date:  1977-06-24       Impact factor: 0.628

4.  Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.

Authors:  M Morichau-Beauchant; G Houin; P Mavier; C Alexandre; D Dhumeaux
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

5.  [Treatment failure of cimetidine in duodenal ulcer (author's transl)].

Authors:  R Gugler; H G Rohner; A A Somogyi
Journal:  Dtsch Med Wochenschr       Date:  1982-07-09       Impact factor: 0.628

6.  Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man?

Authors:  P Bauerfeind; T Cilluffo; C J Fimmel; C Emde; C von Ritter; W Kohler; R Gugler; T Gasser; A L Blum
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

7.  Action of ethanol and some alcoholic beverages on gastric acid secretion and release of gastrin in humans.

Authors:  M V Singer; C Leffmann; V E Eysselein; H Calden; H Goebell
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

8.  Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.

Authors:  V Savarino; G S Mela; P Scalabrini; E Di Timoteo; M R Magnolia; G Celle
Journal:  Digestion       Date:  1987       Impact factor: 3.216

9.  Peptic ulceration in patients with chronic liver disease.

Authors:  A P Kirk; J S Dooley; R H Hunt
Journal:  Dig Dis Sci       Date:  1980-10       Impact factor: 3.199

10.  [Reduced suppression of gastric acid by ranitidine in severe reflux esophagitis. A pilot study].

Authors:  H Koop; M Klein; A Bauer; R Arnold
Journal:  Z Gastroenterol       Date:  1988-07       Impact factor: 2.000

View more
  8 in total

1.  H2-receptor antagonist nonresponders and omeprazole.

Authors:  S Walker; G Treiber; A Sarem-Aslani; U Klotz
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

2.  Gastric emptying in non-responders to H2-receptor antagonists.

Authors:  S Walker; J Meinke; U Klotz; G Treiber; J C Bode
Journal:  Klin Wochenschr       Date:  1990-10-03

3.  Mucosal lesions of the stomach in liver cirrhosis with a special reference to phospholipid metabolism.

Authors:  Y Hosokawa
Journal:  Gastroenterol Jpn       Date:  1991-06

4.  Peptic ulcer surgery in patients with liver cirrhosis.

Authors:  T Lehnert; C Herfarth
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

Review 5.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

6.  Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements.

Authors:  J C Delchier; F Roudot-Thoraval; L Stanescu; M C Deharvengt; L Elouaer Blanc
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

7.  Inadequate response to H2-receptor antagonists. Absence of parietal cell cAMP-stimulating autoantibodies.

Authors:  C Bergmann; A Sarem-Aslani; D Ratge; P Fritz; S Walker; H Wisser; U Klotz
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

8.  Absence of antibodies stimulating H2-receptor mediated cyclic adenosine monophosphate (cAMP) production in peptic ulcer disease.

Authors:  A Sarem-Aslani; C Bergmann; S Walker; D Ratge; U Klotz; H Wisser
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.